Clearmind Advances CMND-100 into AUD Patients After Safety Milestone
Event summary
- Clearmind's CMND-100 achieved primary safety endpoint in Phase I/II trial Part A, advancing to Parts B and C.
- Part B will evaluate CMND-100 in moderate-to-severe Alcohol Use Disorder (AUD) patients for the first time.
- Part C will assess 160 mg daily dose over five consecutive days in healthy participants.
- Trial conducted at Johns Hopkins, Yale School of Medicine, and Israeli medical centers.
The big picture
Clearmind's advancement into AUD patients marks a critical shift from safety to efficacy testing in a $45B global alcohol disorder treatment market. The neuroplastogen approach differentiates it from psychedelic competitors by targeting adaptive neuroplasticity without hallucinogenic effects, potentially enabling outpatient administration models.
What we're watching
- Clinical Efficacy
- How CMND-100's potential to reduce alcohol consumption and craving will manifest in AUD patients.
- Regulatory Pathway
- Whether the non-hallucinogenic profile accelerates FDA approval compared to psychedelic alternatives.
- Market Differentiation
- The pace at which Clearmind can establish CMND-100 as a scalable treatment without intensive clinical supervision.
Related topics